MITRAFIT- Cardinal Adjustable Mitral Repair Follow-up International Postmarketing Surveillance (PMS) (MITRAFIT)
MITRAFIT Cardinal Adjustable Mitral Repair Follow-up International Postmarketing Surveillance (PMS)
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age > 18 years
- Patient is a candidate for mitral valve repair, with our without concomitant procedures.
- Subject is willing to give informed consent for collection of his/her clinical data.
Exclusion Criteria:
- Severe organic lesions with retracted chordae
- Congenital malformations with lack of valvular tissue
- Severe valvular calcifications
- Evolving bacterial endocarditis
- Known Sensitivity to Nickel or Chromium
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
• Ability of the Cardinal ring to reduce mitral valve regurgitation
Time Frame: 30 day
|
30 day
|
|
|
• Percentage of patients in whom the size of the ring is adjusted
Time Frame: 6 months
|
6 months
|
|
|
• Technical feasibility of adjustment.
Time Frame: 6 months
|
The ability of the surgeon to adjust the Cardinal ring when required, will be measured on a scale of 1-3 (1- successfull, 3- unsuccessful)
|
6 months
|
|
• The occurrence of serious device related adverse events in all patients.
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Ottavio Alfieri, Prof, MD, Hospital San Raffaele, Milan, Italy
- Principal Investigator: Nicolas Doll, Prof, MD, SANA Herzchirurgie Stuttgart , Germany
- Principal Investigator: Ehud Raanani, Prof, MD, Sheba medical center
- Principal Investigator: Patrik Nataf, Prof, MD, Bichat Hospital, Paris, France
- Principal Investigator: Volkmar Falk, Prof, MD, Zurich University, Zurich, Switzerland
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- VC1-2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.